Thus, the use of thalidomide in MS has been suggested, considering its protective action against endothelial damage induced by TNF-α [194,195], reduced leukocyte chemotaxis and phagocyte activity [196], inhibition of IFN-γ and IL-12 [197], co-stimulation of CD8+ lymphocytes [198]. This evidence concerns the gene IFNG and myeloid sarcoma.